{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "VSTM",
  "name": "Verastem, Inc.",
  "url": "https://orbyd.app/dossiers/VSTM/",
  "json_url": "https://orbyd.app/dossiers/VSTM.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "The dormant-tape problem flagged in July resolved: Q2 (2026-08-06) put net product revenue at $25.1M vs $23.093M consensus, the Oberland royalty deal funds runway into H2 2027 without equity, and the vague \"H2 2026\" VS-7375 readout is now guided to October. Price went $5.53 (07-12) to $6.74 (08-07) — the binary is dated, but it sits outside 30 days.",
  "invalidation_trigger": "A weekly close below $5.50 gives back the entire post-Q2 advance and returns price to the July shelf ($5.53 close, 2026-07-12); the October 2026 VS-7375 response-rate update arriving without cohort data that separates it from competing oral KRAS G12D programs would compound the break.",
  "catalyst_date": "2026-08-28",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "oncology-immunology",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "AVMAPKI FAKZYNJA CO-PACK holds accelerated approval (FDA, 2025-05-08); RAMP 301 confirmatory topline is guided to mid-2027.",
    "The Oberland facility is a royalty financing secured against AVMAPKI FAKZYNJA revenue — non-dilutive to shareholders but an encumbrance on the commercial asset.",
    "Runway is guided into H2 2027 on a pro forma $201.4M cash basis, while Phase 3 enrollment is targeted to begin H1 2027.",
    "October 2026 VS-7375 data is preliminary Phase 2 at roughly 20 patients per tumor type — cohort sizes that do not support cross-trial superiority claims.",
    "Reporting cadence in 2026 has been 2026-05-07 (Q1) and 2026-08-06 (Q2); Q3 date is not yet confirmed by the company."
  ],
  "body_markdown": "## Current Thesis\nThe July read on this name was that an accelerating KRAS science narrative sat on top of a tape that would not confirm it — pipeline optionality near cash value, a data catalyst with no date, and a financing decision on the clock. Three of those four conditions changed inside four weeks. The 2026-08-06 Q2 print delivered net product revenue of $25.1M against $23.093M consensus and a GAAP loss of $0.35 per share against a $(0.43) estimate; the company put the previously undated VS-7375 update in October 2026; and a non-dilutive royalty financing with Oberland Capital — up to $75M, $50M funding at closing on 2026-08-28 — pushed guided runway from H1 2027 to into H2 2027 without an equity raise. Price moved from $5.53 at the 2026-07-12 close to $6.74 on 2026-08-07, and RSI(14) sits at 68.1. What an investor is buying now is a commercial LGSOC franchise that management expects to be self-sustaining by end-2026 wrapped around a single dated binary: preliminary Phase 2 response rates for oral KRAS G12D inhibitor VS-7375 across pancreatic, lung and colorectal cancer, roughly 20 patients per tumor type, in October. The narrative leg is confirmation that the commercial base can fund the KRAS G12D land-grab — but the readout that reprices it is roughly two months out, and the intervening window is thin.\n\n## Bull Case\n- Q2 2026 (reported 2026-08-06): total revenue $40.1M versus $2.1M in Q2 2025; AVMAPKI FAKZYNJA CO-PACK net product revenue $25.1M, ahead of the $23.093M consensus; GAAP net loss $34.7M, or $0.35 per share, against a $(0.43) estimate.\n- The catalyst gap closed. Updated VS-7375 clinical data across PDAC, NSCLC and CRC — response rates in approximately 20 patients per tumor type — is guided to October 2026, replacing the \"second half 2026\" language that left July with nothing to trade against.\n- Three registration-directed Phase 2 trials are dosing inside six weeks: TARGET-D 201 (2L metastatic PDAC) first patient 2026-06-16, TARGET-D 202 (2L/3L NSCLC) 2026-07-22, TARGET-D 203 (metastatic CRC) 2026-07-28. Phase 2 enrollment completion is targeted by end-2026, an FDA meeting on Phase 3 before year-end 2026, and Phase 3 enrollment initiation in H1 2027.\n- Financing came non-dilutive. Cash and investments were $136.4M at 2026-06-30; pro forma $201.4M including the Oberland facility and a $15M COPIKTRA sales milestone. The optional second Oberland tranche of up to $25M is available if quarterly worldwide net sales of the co-pack reach $40M before 2027-05-15.\n- Sell-side targets remain multiples of the 2026-08-07 close of $6.74 even after two trims: Guggenheim Buy, target cut to $12 on 2026-08-07; RBC Outperform, target cut to $14 on 2026-07-07; HC Wainwright and BTIG both at $18, reiterated 2026-06-24.\n\n## Bear Case\n- Targets were cut into the rally, not raised. RBC took $14 on 2026-07-07 and Guggenheim took $12 on 2026-08-07 — ratings held, numbers came down, while the stock advanced.\n- The October update is preliminary Phase 2 data at roughly 20 patients per tumor type. Cohorts that size support directional reads, not cross-trial superiority claims against Revolution Medicines' RMC-9805 or the Astellas and BMS programs chasing the same target.\n- The $25M contingent Oberland tranche requires quarterly co-pack net sales of $40M before 2027-05-15, against $25.1M booked in Q2 2026. That is a meaningful step-up on a rare-indication launch.\n- The royalty structure is non-dilutive but encumbers the commercial asset's revenue stream, and Phase 3 enrollment is targeted to begin H1 2027 — spend that lands before runway guided \"into the second half of 2027\" is exhausted.\n- Accelerated-approval risk is unresolved for a year: RAMP 301 confirmatory topline is guided to mid-2027, sitting underneath the entire commercial floor.\n- Despite the improved print, price is 37.4% below the 52-week high of $10.77 as of 2026-08-07. The move off July lows has not reclaimed the June highs.\n\n## Setup & Price Structure\n- Last completed daily close $6.74 (2026-08-07) against $5.53 on 2026-07-12. Three-month return +37.8%. RSI(14) 68.1. Distance from the 52-week high of $10.77: -37.4%.\n- Life-cycle: **ACCELERATING**, and dated by three events inside six weeks — the 2026-07-28 CRC dosing announcement, the 2026-08-06 revenue and EPS beat, and the 2026-08-07 Guggenheim note. Participation is expanding off a July base rather than fading out of a mainstream top; the name is not near its own high, which is inconsistent with a saturated setup.\n- Crowding and positioning observables, stated as observables: RSI(14) at 68.1 is in the upper band but not extreme; a +37.8% three-month advance means fresh entries chase a move already made; the earnings print is behind (2026-08-06), so no company-reported number lands inside 30 days to either confirm or break the ramp; the financing question was answered with royalty capital rather than an equity issuance into strength, removing the specific dilution overhang flagged in the prior note; two banks lowered targets while maintaining Buy-equivalent ratings in the last five weeks.\n- The structure that matters is the July shelf near the $5.53 close of 2026-07-12 and the post-print advance above it. The gap between $6.74 and the $10.77 high is unfilled overhead supply from the June data spikes.\n\n## Catalyst Calendar (next 30 days)\n- **2026-08-28** — Oberland Capital royalty financing closing, $50M funding. Converts the pro forma $201.4M cash figure into actual cash and validates the runway-into-H2-2027 guidance.\n- **~2026-09-08 (est.)** — no company-scheduled event; the window between the Q2 print and October data carries conference abstract drops and competitor KRAS G12D disclosures as the realistic sources of headline risk.\n- Beyond the window, dated for reference: **~2026-10-31 (est.)** VS-7375 TARGET-D response-rate update across PDAC/NSCLC/CRC; **~2026-11-05 (est.)** Q3 2026 print on the 2026-05-07 / 2026-08-06 reporting cadence; **~2026-12-31 (est.)** FDA meeting on Phase 3 design and targeted Phase 2 enrollment completion.\n\n## What Would Change Our Mind\nThe structure that has to hold is the July base the post-print advance was built on. A weekly close below $5.50 erases the entire move off the 2026-07-12 close of $5.53 and puts the equity back to pricing VS-7375 near option value, which would say the market read the Q2 beat as a one-quarter launch artifact rather than the start of a self-funding commercial base. Three fundamental conditions would independently break the frame: the Oberland closing on 2026-08-28 failing to fund, which reopens the equity-issuance question the royalty deal was meant to close; the October 2026 update arriving with response rates in the ~20-patient cohorts that do not distinguish VS-7375 from competing oral KRAS G12D inhibitors; and co-pack net sales flatlining below the $25.1M Q2 level at the Q3 print, which would put the $40M quarterly bar for the contingent $25M tranche out of reach and shorten the runway math. Conversely, a clean October dataset plus continued sequential product-revenue growth would move the frame from binary-catalyst to a funded commercial-plus-pipeline story.\n\n## Correlation Notes\n- Direct read-through from competing oral KRAS G12D programs — Revolution Medicines (RMC-9805), Astellas and BMS. A stronger PDAC dataset from any of them ahead of or alongside the October update compresses VSTM's differentiation regardless of its own numbers.\n- Small-cap clinical-stage biotech beta: the name trades with XBI-type risk appetite and rate expectations, and a $136.4M cash balance against Phase 3 spend starting H1 2027 makes it sensitive to any shift in biotech financing conditions.\n- Partial decoupling from pure-pipeline comps: with $25.1M of quarterly product revenue and a royalty financing secured against it, part of the equity now trades on launch-curve execution rather than binary trial risk alone.\n- KRAS-franchise sentiment moves on conference calendars (ASCO, ESMO, AACR) more than on macro; abstract-title releases ahead of those meetings have historically moved this cohort before the data itself is public.",
  "first_seen": "2026-07-12",
  "last_analyzed": "2026-08-09T19:08:43+00:00",
  "last_synthesized": "2026-08-09",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}